Heparin inhibits osteoclastic differentiation and function.

Area of Science:

• Biochemistry
• Cell Biology
• Immunology

Background:

• Osteoclastogenesis, the formation of bone-resorbing cells, is a critical process in bone remodeling.
• Receptor activator of NF-kappaB ligand (RANKL) is a key cytokine regulating osteoclast differentiation.
• Glycosaminoglycans (GAGs) are complex carbohydrates with diverse biological roles, including potential immunomodulatory effects.

Purpose of the Study:

• To investigate the in vitro effects of various GAGs on the differentiation, proliferation, and function of mouse monocytic RAW 264.7 cells.
• To elucidate the mechanism by which heparin, a specific GAG, influences RANKL-induced osteoclastogenesis.

Main Methods:

• RAW 264.7 cells were cultured with RANKL and various GAGs.
• Osteoclast differentiation was assessed by tartrate-resistant acid phosphatase (TRAP) staining and multinucleated cell formation.
• Bone resorption activity was measured by counting resorption pits.
• Cell proliferation was evaluated using MTT assay, and c-Src protein levels were determined by immunoblot analysis.
• Heparin-RANKL binding was confirmed using HiTrap heparin column chromatography, Western blotting, and quartz-crystal microbalance.

Main Results:

• Heparin significantly suppressed RANKL-induced osteoclast differentiation, TRAP activity, and bone resorption.
• Other tested GAGs did not exhibit inhibitory effects on osteoclastogenesis.
• Heparin did not affect RAW 264.7 cell proliferation.
• Heparin reduced c-Src protein levels and demonstrated direct binding to RANKL, which was confirmed by biophysical methods.

Conclusions:

• Heparin exerts an inhibitory effect on RANKL-induced osteoclastogenesis.
• This inhibition is mediated by the direct binding of heparin to RANKL, thereby interfering with its function.
• Heparin represents a potential therapeutic agent for conditions involving excessive bone resorption.